Floatz logo

Doxycycline

Lymphangioleiomyomatosis

University of NottinghamSmall moleculePhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Lymphangioleiomyomatosis cohort.

Asset / SponsorPhaseRating
Rapamycin
University of Cincinnati
Phase 2BB
Everolimus
University of Cincinnati
Phase 3BB
SIMVASTATIN
University of Pennsylvania
Phase 1/2CCC
Valproic Acid
M.D. Anderson Cancer Center
Phase 1CC
Cetuximab
M.D. Anderson Cancer Center
Phase 1CC
Temsirolimus
M.D. Anderson Cancer Center
Phase 1CC
Rapamycin
Dana-Farber Cancer Institute
Phase 2NR

Same molecule, other indications

Doxycycline is also rated in:

tuberous sclerosisDormant
BB
Indicative ·
64 / 100
View asset →
Chronic Pelvic Pain SyndromeDormant
B
Indicative ·
62 / 100
View asset →
FAP-Familial Adenomatous PolyposisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →